INTRODUCTION
Inclusion body myositis (IBM) is an acquired myopathy of both
inflammatory and degenerative nature with an increased incidence in
elderly and male patients. It is a rare condition with an unclear
etiology, occurring with neurodegenerative findings in addition to a
cytotoxic T cell-mediated immune response (1). Although several factors
have been associated with the development of IBM, tyrosine kinase
inhibitors seems safer in that issue and only one case of IBM developed
after the use of dasatinib has been reported so far (2). Here, we report
a case of IBM, associated with the prolonged use of imatinib which is
the first case in literature.